MedTrace Logo

Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

NCT02160223 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2014-12-09

No results posted yet for this study

Summary

Incomplete recovery of neuromuscular function after surgery can lead to respiratory complications. Patients with obstructive sleep apnea (OSA) are prone to respiratory complications after surgery. Neostigmin and sugammadex are used for neuromuscular reversal.

The aim of this study was to compare sugammadex and neostigmin regarding efficacy, incidence of respiratory complications and cost in patients undergoing surgery for OSA

Conditions

Interventions

DRUG

Sugammadex

Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery

DRUG

Neostigmine

Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery

Sponsors & Collaborators

  • Diskapi Teaching and Research Hospital

    lead OTHER

Principal Investigators

  • Dilek yazicioglu, Dr · Dişkapı yildirim beyazit Teaching and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02160223 on ClinicalTrials.gov